Devjit Tripathy1, Jeff E Cobb, Walter Gall, Klaus-Peter Adam, Tabitha George, Dawn C Schwenke, MaryAnn Banerji, George A Bray, Thomas A Buchanan, Stephen C Clement, Robert R Henry, Abbas E Kitabchi, Sunder Mudaliar, Robert E Ratner, Frankie B Stentz, Peter D Reaven, Nicolas Musi, Ele Ferrannini, Ralph A DeFronzo. 1. Texas Diabetes Institute (D.T., N.M., R.A.D.), University of Texas Health Science Center, San Antonio, Texas 78207; South Texas Veterans Health Care System (D.T., N.M., R.A.D.), Audie L. Murphy Division, San Antonio, Texas 78228; Metabolon, Inc (J.E.C., W.G., K.-P.A., T.G.), Durham, North Carolina 27713; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing and Health Care Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85004; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center/Louisiana State University (G.A.B.), Baton Rouge, Louisiana 70808; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California 90033; VA San Diego Healthcare System and University of California at San Diego (R.R.H., S.M.), San Diego, California 92161; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee, Memphis, Tennessee 38163; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782; and Department of Clinical and Experimental Medicine (E.F.), CNR Institute of Clinical Physiology, 56126 Pisa, Italy.
Abstract
OBJECTIVE: The objective was to test the clinical utility of Quantose M(Q) to monitor changes in insulin sensitivity after pioglitazone therapy in prediabetic subjects. Quantose M(Q) is derived from fasting measurements of insulin, α-hydroxybutyrate, linoleoyl-glycerophosphocholine, and oleate, three nonglucose metabolites shown to correlate with insulin-stimulated glucose disposal. RESEARCH DESIGN AND METHODS: Participants were 428 of the total of 602 ACT NOW impaired glucose tolerance (IGT) subjects randomized to pioglitazone (45 mg/d) or placebo and followed for 2.4 years. At baseline and study end, fasting plasma metabolites required for determination of Quantose, glycated hemoglobin, and oral glucose tolerance test with frequent plasma insulin and glucose measurements to calculate the Matsuda index of insulin sensitivity were obtained. RESULTS:Pioglitazone treatment lowered IGT conversion to diabetes (hazard ratio = 0.25; 95% confidence interval = 0.13-0.50; P < .0001). Although glycated hemoglobin did not track with insulin sensitivity, Quantose M(Q) increased in pioglitazone-treated subjects (by 1.45 [3.45] mg·min(-1)·kgwbm(-1)) (median [interquartile range]) (P < .001 vs placebo), as did the Matsuda index (by 3.05 [4.77] units; P < .0001). Quantose M(Q) correlated with the Matsuda index at baseline and change in the Matsuda index from baseline (rho, 0.85 and 0.79, respectively; P < .0001) and was progressively higher across closeout glucose tolerance status (diabetes, IGT, normal glucose tolerance). In logistic models including only anthropometric and fasting measurements, Quantose M(Q) outperformed both Matsuda and fasting insulin in predicting incident diabetes. CONCLUSIONS: In IGT subjects, Quantose M(Q) parallels changes in insulin sensitivity and glucose tolerance with pioglitazone therapy. Due to its strong correlation with improved insulin sensitivity and its ease of use, Quantose M(Q) may serve as a useful clinical test to identify and monitor therapy in insulin-resistant patients.
RCT Entities:
OBJECTIVE: The objective was to test the clinical utility of Quantose M(Q) to monitor changes in insulin sensitivity after pioglitazone therapy in prediabetic subjects. Quantose M(Q) is derived from fasting measurements of insulin, α-hydroxybutyrate, linoleoyl-glycerophosphocholine, and oleate, three nonglucose metabolites shown to correlate with insulin-stimulated glucose disposal. RESEARCH DESIGN AND METHODS: Participants were 428 of the total of 602 ACT NOW impaired glucose tolerance (IGT) subjects randomized to pioglitazone (45 mg/d) or placebo and followed for 2.4 years. At baseline and study end, fasting plasma metabolites required for determination of Quantose, glycated hemoglobin, and oral glucose tolerance test with frequent plasma insulin and glucose measurements to calculate the Matsuda index of insulin sensitivity were obtained. RESULTS:Pioglitazone treatment lowered IGT conversion to diabetes (hazard ratio = 0.25; 95% confidence interval = 0.13-0.50; P < .0001). Although glycated hemoglobin did not track with insulin sensitivity, Quantose M(Q) increased in pioglitazone-treated subjects (by 1.45 [3.45] mg·min(-1)·kgwbm(-1)) (median [interquartile range]) (P < .001 vs placebo), as did the Matsuda index (by 3.05 [4.77] units; P < .0001). Quantose M(Q) correlated with the Matsuda index at baseline and change in the Matsuda index from baseline (rho, 0.85 and 0.79, respectively; P < .0001) and was progressively higher across closeout glucose tolerance status (diabetes, IGT, normal glucose tolerance). In logistic models including only anthropometric and fasting measurements, Quantose M(Q) outperformed both Matsuda and fasting insulin in predicting incident diabetes. CONCLUSIONS: In IGT subjects, Quantose M(Q) parallels changes in insulin sensitivity and glucose tolerance with pioglitazone therapy. Due to its strong correlation with improved insulin sensitivity and its ease of use, Quantose M(Q) may serve as a useful clinical test to identify and monitor therapy in insulin-resistant patients.
Authors: Mandeep Bajaj; Rais Baig; Swangjit Suraamornkul; Lou Jean Hardies; Dawn K Coletta; Gary W Cline; Adriana Monroy; Shailja Koul; Apiradee Sriwijitkamol; Nicolas Musi; Gerald I Shulman; Ralph A DeFronzo Journal: J Clin Endocrinol Metab Date: 2010-02-15 Impact factor: 5.958
Authors: Karsten Suhre; Christa Meisinger; Angela Döring; Elisabeth Altmaier; Petra Belcredi; Christian Gieger; David Chang; Michael V Milburn; Walter E Gall; Klaus M Weinberger; Hans-Werner Mewes; Martin Hrabé de Angelis; H-Erich Wichmann; Florian Kronenberg; Jerzy Adamski; Thomas Illig Journal: PLoS One Date: 2010-11-11 Impact factor: 3.240
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: Ele Ferrannini; Andrea Natali; Stefania Camastra; Monica Nannipieri; Andrea Mari; Klaus-Peter Adam; Michael V Milburn; Gabi Kastenmüller; Jerzy Adamski; Tiinamaija Tuomi; Valeriya Lyssenko; Leif Groop; Walter E Gall Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461
Authors: Kim M Huffman; Cris A Slentz; Lori A Bateman; Dana Thompson; Michael J Muehlbauer; James R Bain; Robert D Stevens; Brett R Wenner; Virginia Byers Kraus; Christopher B Newgard; William E Kraus Journal: Diabetes Care Date: 2010-10-04 Impact factor: 19.112
Authors: Rachel E Walker; Jennifer L Ford; Raymond C Boston; Olga V Savinova; William S Harris; Michael H Green; Gregory C Shearer Journal: Am J Physiol Endocrinol Metab Date: 2020-01-07 Impact factor: 4.310
Authors: Bradley A Perkins; C Thomas Caskey; Pamila Brar; Eric Dec; David S Karow; Andrew M Kahn; Ying-Chen Claire Hou; Naisha Shah; Debbie Boeldt; Erin Coughlin; Gabby Hands; Victor Lavrenko; James Yu; Andrea Procko; Julia Appis; Anders M Dale; Lining Guo; Thomas J Jönsson; Bryan M Wittmann; Istvan Bartha; Smriti Ramakrishnan; Axel Bernal; James B Brewer; Suzanne Brewerton; William H Biggs; Yaron Turpaz; J Craig Venter Journal: Proc Natl Acad Sci U S A Date: 2018-03-19 Impact factor: 11.205